Protalix BioTherapeutics PLX
NYSE PLX
$3.13 +0.28 (+9.62%)
As of: Nov 11, 2026 · 3:59 PM EST

Protalix BioTherapeutics (PLX) Beginning Cash Balance (2011 - 2013)

Updated

Analysis

Protalix BioTherapeutics (PLX) Beginning Cash Balance (2011 - 2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Protalix BioTherapeutics 230.43 Mn 59.88 Mn 14.05 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 52.04 Mn
Dec 31, 2012 27.00 Mn
Dec 31, 2011 35.90 Mn
API Access

Protalix BioTherapeutics Beginning Cash Balance API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=beginning-cash-balance&ticker=PLX&period=max&api_key=YOUR_API_KEY